Results 101 to 110 of about 857 (121)

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody–drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Clinical Cancer Research, 2022
Sylvie Rottey, Martijn P Lolkema, Paul De Souza   +2 more
exaly  

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

Clinical Cancer Research, 2021
Martin Gutierrez, Victor Moreno, Anthony J Olszanski   +2 more
exaly  

Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4

Journal of Medicinal Chemistry, 2022
E Scott Priestley, Jeremy M Richter, Jianqing Li   +2 more
exaly  

Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants

Clinical Pharmacology in Drug Development, 2021
Santanu Dutta
exaly  

New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans

Platelets, 2022
Samira Garonzik, Michel Bouvier, Jing Yang   +2 more
exaly  

Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents

Frontiers in Cell and Developmental Biology, 2021
Chung-Pu Wu, Megumi Murakami, Yu-Shan Wu
exaly